Processa Pharmaceuticals (PCSA) announces the appointment of Russell Skibsted as Chief Financial Officer, CFO, effective immediately. Skibsted succeeds James Stanker, who is retiring and staying on in an advisory role to assist in the transition. Most recently, Skibsted served as Senior Vice President and CFO of Alimera Sciences (ALIM).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCSA:
- Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
- Processa announces results from preliminary eval of Phase 1b trial with NGC-Cap
- Processa Pharmaceuticals files $50M mixed securities shelf